Predictive Oncology Faces Nasdaq Delisting Notice

The latest update is out from Predictive Oncology ( (POAI) ).

On June 9, 2025, Predictive Oncology Inc. received a notice from Nasdaq indicating its failure to meet the minimum stockholders’ equity requirement, leading to a potential delisting from the Nasdaq Capital Market. The company has requested a hearing to appeal this decision, which temporarily halts the delisting process, but there is no guarantee of a favorable outcome. Predictive Oncology is exploring options to regain compliance with Nasdaq’s listing requirements.

The most recent analyst rating on (POAI) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Predictive Oncology stock, see the POAI Stock Forecast page.

Spark’s Take on POAI Stock

According to Spark, TipRanks’ AI Analyst, POAI is a Neutral.

Predictive Oncology’s stock score is primarily impacted by its poor financial performance, characterized by declining revenues and negative profit margins. Additionally, technical analysis shows bearish momentum, and valuation metrics indicate high risk. The absence of earnings call data and corporate events further emphasizes the reliance on financial and technical factors.

To see Spark’s full report on POAI stock, click here.

More about Predictive Oncology

Predictive Oncology Inc. operates in the biotechnology industry, focusing on developing and providing innovative solutions for cancer treatment through the use of artificial intelligence and machine learning.

Average Trading Volume: 2,703,392

Technical Sentiment Signal: Strong Sell

Current Market Cap: $8.84M

For a thorough assessment of POAI stock, go to TipRanks’ Stock Analysis page.